The production threads in the memorable stylings of "Deck the Halls," one of the most iconic Christmas songs of all time. But ...

Bradley Cooper's Is This Thing On? is the latest fictional film to mine humor and pathos from life on the stand-up stage—but ...

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease ...

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. BioMarin Pharmaceuticals Inc.

In the first of a series looking at production in the regions, Matthew Corrigan turns the spotlight on Greater Manchester, ...

Jamaican superstar Sean Paul is set to return to Bulgaria on May 13, 2026, with the Rise Jamaica concert at Vidas Art Arena, organized by Fest Team. Fourteen years after his first performance in the ...

BioMarin’s $4.8 billion all-cash acquisition of Amicus Therapeutics significantly expands its rare disease portfolio with established Fabry and Pompe franchises, adds late-stage pipeline upside, and ...

BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total ...

BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with ...

From Clipse to Nas, and from the underground to the global stage, hip-hop returned to its foundation — prioritizing culture, ...

BioMarin Pharmaceutical’s strong rare disease drug portfolio and Amicus acquisition drive a ‘Buy’ rating. Click here to read my latest analysis of BMRN stock.

Music journalist Kelly Washington travelled to the Playa Pacha at the FIVE Luxe Hotel to profile Peggy Gou, the queen of ...